Navigation Links
Adeona Announces Second Quarter 2010 Profitability and Achievements
Date:8/16/2010

5 million upon filing of a New Drug Application with the Food and Drug Administration for flupirtine for fibromyalgia and $10 million upon marketing approval.
  • As of today, 97 out of 150 patients have been enrolled in the Trimesta clinical trial studying whether 8 mg of oral Trimesta taken daily over a 2 year period would reduce the rate of relapses in female relapsing-remitting multiple sclerosis patients. The randomized, double-blind, placebo-controlled clinical trial is currently underway at 16 centers in the United States. The clinical trial has received approximately $5.9 million in grant funding to date.

  • As of today, 54 out of 60 subjects have been enrolled in the Zinthionein clinical study testing the therapeutic effects of Adeona's proprietary oral, gastro-retentive, sustained-release zinc and cysteine formulation on cognition in Alzheimer's disease and mild cognitive impairment subjects. The randomized, double-blind, placebo-controlled study is currently underway at 3 centers in the United States. Study subjects are being assessed at 3 and 6 months for serum parameters of zinc and copper as well as changes in cognitive function using standard Alzheimer's disease clinical tests. Adeona expects completion of this clinical study in the first quarter of 2011.

  • HartLab, now renamed Adeona Clinical Laboratory, has added microbiology testing and pediatric testing services. The number of clients at the CLIA-certified diagnostic testing lab has doubled over the past few months. The lab is now open 7 days a week and offers walk-in phlebotomy services. Increased commercialization efforts are starting to result in increases in recurring revenues. Adeona Clinical Laboratory has been obtaining higher rates of reimbursement for the serum-based CopperProof Panel test.


    '/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Researchers from the North American Menopause Society (NAMS) found ... too high, 1 putting women at risk for ... close to menopause are commonly told to take supplements ... as osteoporosis, to which they are particularly prone. ... calcium they typically get through their food sources before ...
(Date:7/23/2014)... 2014 This September leading clinicians in orthodontics ... Vegas for DOCtalk 2014 —a "Dynamic ... thinker and private practitioner Dr. David Sarver , ... discuss clinical and practice management efficiency and high quality ... opportunity to welcome fresh thinking and join a community ...
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... a pharmaceutical company dedicated to improving healthcare through ... range of prescription and over-the-counter ("OTC") products, today ... Mr. Tony Liu and Chief Financial Officer, Ms. ...
... that a new market research report is available in ... in China http://www.reportlinker.com/p0363587/The-Top-10-CMOs-in-China.html ... and future outlook of CMO industry in China. It ... the top 10 CMOs. Other leading players are also ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds The Top 10 CMOs in China 2
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... Adipic acid is an intermediate chemical ... plastic, often referred to as engineering thermoplastics. These ... the monomers employed. Due to the high production ... increasing number of developing countries, the Asia-Pacific region ... by Europe and North America. Adipic acid in ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) -- Children and teens who lose ... death in adulthood, a new study suggests. People who ... 50 percent greater risk of death during the study period ... parent, according to the report. Although the study found ... risk of premature death, it wasn,t designed to prove cause-and-effect. ...
(Date:7/23/2014)... ill patients arriving at the emergency department, the ... amnesia for rapid, life-saving intubation, despite decades-old studies ... results of a systematic review of 10 recent ... a "wonder drug" are published online in ... of Ketamine on Intracranial and Cerebral Perfusion Pressure ...
(Date:7/23/2014)... 2014 SafeUseNow? , a ... developed by Principled Strategies , today announced ... California . Utilizing SafeUseNow’s patent-pending risk model, Partnership ... misusing and abusing controlled substance drugs, particularly prescription ... its members. , The agreement with Partnership HealthPlan ...
Breaking Medicine News(10 mins):Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Adipic Acid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 2Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 3Health News:Partnership HealthPlan of California Signs Program Participation Agreement with SafeUseNow 4
... Bulgaria is to ban the imports of live birds, eggs ... reported suspected bird flu outbreaks. The first case of bird ... province near the Aegean Sea in Western Turkey. Following the ... being slaughtered in order to prevent the spread of the ...
... new study has linked beta-carotene to heart diseases. The ... of deaths in elderly with heart diseases. ,The ... significant after considering other risk factors, according to the ... previous studies that either suggest the carotenoid raises the ...
... novel initiative to combat the spread of childhood obesity, ... of the William J. Clinton Foundation and the American ... a partnership with Nickelodeon's award-winning Let's Just Play pro-social ... a comprehensive media and public awareness campaign, encouraging young ...
... nutritionally good compounds. Lot of research is being done ... herbs, fruits, and vegetables, slowed the growth of prostate ... ,Previous studies already found flavonoids (found in fruits and ... of cancers. ,The current study was intended to ...
... its major 29 hospitals to share information about its ... and interlinking of data would be helpful to citizen ... the case history and treatment provided to this patient. ... with different hospital departments. From a patient's personal information ...
... linked to a number of psychiatric disorders, including ... Early smoking is shown to increase the risk ... disorder, generalized anxiety disorder), and that presence of ... risk for later development of nicotine dependence. ...
Cached Medicine News:Health News:A New Initiative To Fight Childhood Obesity 2Health News:Prostate tumour growth suppressed by flavonoids 2Health News:Delhi Government To Interlink All Major Hospitals Through e-Governance 2Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2
... injectable low osmolar, nonionic, contrast media ... biologically inert when injected intra-arterially. Each ... of ioversol, 3.6 mg of tromethamine ... of edetate calcium disodium as a ...
... is a non-ionic monomeric contrast medium for ... and children. After a decade of clinical ... examinations, IMAGOPAQUE has proven to be a ... hundreds of radiology departments.Results from large multicentre ...
... ProHance® (gadoteridol) is a contrast medium ... form of a sterile, apyrogenic solution for ... contrast enhancement of the brain, spine and ... with unenhanced MRI) of lesions with abnormal ...
... Advanced Magnetics' contrast agent for use with MRI ... the first organ-specific MRI contrast agent to be ... agent is taken up by macrophages found only ... tumors. The liver is a principal site for ...
Medicine Products: